Medicare Appeals Rule Expedited By Visudyne Settlement; MCAC To Convene
This article was originally published in The Gray Sheet
Executive Summary
CMS' Medicare Coverage Advisory Committee will review initial data from QLT, Inc.'s Phase III trial investigating Visudyne (verteporfin) ocular photodynamic therapy in age-related macular degeneration patients with occult lesions